We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look ...

Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...

Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for ...

Tenaya首席医疗官Whit Tingley医学博士强调了TN-201在临床前研究中实现转导和表达的一致性。该公司预计将在美国心脏病学会科学会议上展示MyPEAK-1临床试验第一组患者的额外数据，高剂量组的初步数据预计将在今年下半年公布。

ATHENS, Greece, March 24, 2025 (GLOBE NEWSWIRE) -- Icon Energy Corp. ("Icon” or the "Company”) (Nasdaq: ICON), an ...

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201SOUTH ...

Take for example, the MYBPC3 mutation known to lead to cardiac arrest at a young age is found in 4.5% of the Indian population but is rare globally. Or, another mutation called LAMB3 that causes a ...

为明确心肌病相关基因变异，研究人员对 40 例土耳其患者行临床外显子组测序（CES），发现MYBPC3变异最多。 心肌病是一种心肌细胞存在缺陷，进而导致心脏功能出现故障的病症。心肌病依据分子和（或）全身改变被分为三大类，且有多个亚型。该疾病的表现与 ...

We look forward to sharing data from both the TN-201 MyPEAK-1 clinical trial for MYBPC3-associated HCM and the RIDGE-1 clinical trial of TN-401 for PKP2-associated ARVC in the months ahead ...

Pipeline and Near-term Catalysts: Tenaya's lead gene therapy candidates are TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy or HCM, and TN-401, targeting PKP2-associated ...